{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:00:24Z","timestamp":1790370024296,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["CPRIT RP 180725"],"award-info":[{"award-number":["CPRIT RP 180725"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijrobp.2026.04.079","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:06:30Z","timestamp":1777590390000},"page":"821-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycoprotein Nonmetastatic B\u207a Myeloid-Derived Suppressor Cells Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-1732","authenticated-orcid":false,"given":"Oscar","family":"Mulvaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandarigoda Gamage","family":"Somatilaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu M.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponciano D.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ariizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.04.079_bib0001","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer, Version 2.2025. Accessed September 2, 2025. https:\/\/www.nccn.org"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0003","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","article-title":"Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: Pooled prospective outcomes from the SHARP consortium","volume":"122","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0006","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.critrevonc.2017.02.026","article-title":"A comprehensive review of immunotherapies in prostate cancer","volume":"113","author":"Maia","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102057","article-title":"Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes","volume":"88","author":"Claps","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0008","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0009","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0010","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: The randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0011","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/1078-0432.CCR-07-0842","article-title":"CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer","volume":"13","author":"Kiniwa","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0012","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-07-2056","article-title":"Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer","volume":"14","author":"Yokokawa","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0013","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0014","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The tumor immune contexture of prostate cancer","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: A comprehensive review","volume":"103","author":"Novysedlak","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0016","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/iju.12086","article-title":"Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison","volume":"20","author":"Brusa","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0017","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-18-0330","article-title":"Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL\/GPNMB antibody restores the in vitro integrity of T cells from cancer patients","volume":"25","author":"Kobayashi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119132","article-title":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","volume":"284","author":"Karpisheh","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0020","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0021","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0022","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/02841860600604611","article-title":"Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma","volume":"45","author":"Wers\u00e4ll","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1752-1947-5-111","article-title":"Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: A case report","volume":"5","author":"Okuma","year":"2011","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0024","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0025","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","article-title":"Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial","volume":"110","author":"Margulis","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0026","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/0008-5472.CAN-09-4446","article-title":"Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation","volume":"70","author":"Kozin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0027","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0028","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1158\/1078-0432.CCR-14-2742","article-title":"Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0029","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1073\/pnas.1613187113","article-title":"Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF","volume":"113","author":"Takeshima","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910600111","article-title":"Nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts","volume":"60","author":"Weterman","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0031","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.4049\/jimmunol.179.9.5778","article-title":"Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation","volume":"179","author":"Chung","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0032","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/blood-2006-11-053769","article-title":"DC-HIL is a negative regulator of T lymphocyte activation","volume":"109","author":"Chung","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-015-0099-5","article-title":"The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells","volume":"13","author":"Gutknecht","year":"2015","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.gene.2008.01.014","article-title":"Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB","volume":"413","author":"Ripoll","year":"2008","journal-title":"Gene"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0035","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/jid.2014.248","article-title":"DC-HIL+ CD14+ HLA-DR no\/low cells are a potential blood marker and therapeutic target for melanoma","volume":"134","author":"Turrentine","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0036","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/1078-0432.CCR-19-2360","article-title":"DC-HIL\/Gpnmb is a negative regulator of tumor response to immune checkpoint inhibitors","volume":"26","author":"Chung","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0037","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0625.2008.00830.x","article-title":"Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte\/keratinocyte adhesion in a RGD-dependent fashion","volume":"18","author":"Tomihari","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0038","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1038\/jid.2014.254","article-title":"DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth","volume":"134","author":"Chung","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0039","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nature Commun"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0040","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0041","doi-asserted-by":"crossref","first-page":"36215","DOI":"10.1074\/jbc.M111.246116","article-title":"The E-box binding factors Max\/Mnt, MITF, and USF1 act coordinately with FoxO to regulate expression of proapoptotic and cell cycle control genes by phosphatidylinositol 3-kinase\/Akt\/glycogen synthase kinase 3 signaling","volume":"286","author":"Terragni","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0042","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1755-148X.2008.00505.x","article-title":"Novel MITF targets identified using a two-step DNA microarray strategy","volume":"21","author":"Hoek","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0043","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s12276-024-01175-5","article-title":"Emerging roles of MITF as a crucial regulator of immunity","volume":"56","author":"Lee","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0044","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood.V96.12.3838","article-title":"Identification of a CD11b(+)\/Gr-1(+)\/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells","volume":"96","author":"Bronte","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0045","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00262-014-1591-2","article-title":"Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer","volume":"63","author":"Idorn","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0046","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0047","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3621496","article-title":"Myeloid-derived suppressor cells and CD68(+)CD163(+)M2-Like macrophages as therapeutic response biomarkers are associated with plasma inflammatory cytokines: A preliminary study for non-small cell lung cancer patients in radiotherapy","volume":"2022","author":"Lv","year":"2022","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0048","article-title":"Effect of external beam radiation therapy and brachytherapy on circulating myeloid-derived suppressor cell populations in patients treated definitively for cervical cancer","volume":"10","author":"Wanhainen","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0049","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41416-023-02230-0","article-title":"Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner","volume":"128","author":"Mao","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069527","article-title":"The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor","volume":"8","author":"Crittenden","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0051","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cytob.21206","article-title":"Complexity and challenges in defining myeloid-derived suppressor cells","volume":"88","author":"Damuzzo","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0052","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1755-148X.2010.00775.x","article-title":"Lighting a path to pigmentation: Mechanisms of MITF induction by UV","volume":"23","author":"Liu","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0053","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1073\/pnas.0705117104","article-title":"SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation","volume":"104","author":"Passeron","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/iju5.12351","article-title":"Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer","volume":"4","author":"Kohada","year":"2021","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0056","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","article-title":"Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children\u2019s Oncology Group","volume":"121","author":"Kopp","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0057","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma","volume":"32","author":"Ott","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.079_bib0058","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626006565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626006565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:06:29Z","timestamp":1790366789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626006565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0360301626006565"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.079","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein Nonmetastatic B\u207a Myeloid-Derived Suppressor Cells Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}